The primary goal of the Supporters of Biozipcode is to support the development of treatments for diabetes and its complications and to help bring the results of ongoing research to the world. Our ultimate mission is to improve the quality of life for diabetes patients worldwide.

Biozipcode, Inc. is focused on researching and developing new diagnostic methods and treatments that target abnormal hematopoietic stem cells, which are considered a key reason why diabetes is difficult to cure. By addressing this root cause, we aim to provide more effective treatments that lead to complete remission rather than just managing the disease. Furthermore, by enabling a true cure, we seek to reduce the medical and economic burden of diabetes treatments, including dialysis and other costly interventions.

Additionally, the development of side-effect-free drugs will be made possible through Biozipcode technology. The Biozipcode (biological postal code), or BIOZIPCODE, is a seven-amino-acid peptide that functions like a biological version of Japan’s postal code system. It binds specifically to targeted organs and cells, allowing precise delivery of therapeutic agents. This technology is set to revolutionize both molecular-level diagnostics and targeted treatments.

The Supporters of Biozipcode is committed to supporting Biozipcode, Inc. in every possible way to achieve two major objectives:

• Developing a complete cure for diabetes
• Creating side-effect-free drugs using Biozipcode technology

The development of a cure for diabetes is based on critical scientific discoveries.

Recent studies have revealed the role of bone marrow-derived cells (BMDCs) in the progression of diabetes. In particular, a subset of BMDCs known as Vcam1-positive short-term hematopoietic stem cells (Vcam1+ ST-HSCs) has been identified as a major contributor to the development of diabetic complications. It is hypothesized that these cells continuously damage pancreatic β-cells, which are essential for insulin production.

Based on this discovery, a treatment combining insulin therapy with the removal of abnormal BMDCs was tested in diabetic mouse models. Researchers found that bone marrow transplantation successfully eliminated abnormal BMDCs, allowing the mice to maintain normal blood sugar levels even after discontinuing insulin therapy. Furthermore, an alternative approach using the HDAC inhibitor givinostat was also found to be effective. Givinostat corrected epigenetic abnormalities in BMDCs, and after treatment discontinuation, both insulin secretion and blood glucose normalization were sustained.

Additionally, this combination therapy was shown to suppress abnormal BMDC migration to the pancreatic islets and thymus, as well as cell fusion events caused by diabetes. However, in diabetic mice that underwent thymectomy (surgical removal of the thymus), the treatment was ineffective. This finding suggests that diabetes is not only a bone marrow disorder but also involves epigenetic dysfunction in the thymus.

These research findings have direct implications for the development of a diabetes cure. The combination therapy of insulin and givinostat has the potential for clinical application as a groundbreaking treatment that aims for complete remission (cure) of diabetes.

For more details, please refer to the Nature Communication Biology research paper.

Yes, direct donations to Biozipcode, Inc. are possible.

The Supporters of Biozipcode initiative, operated by Studio Makyu Co., Ltd., is dedicated to fundraising and business collaboration to support research and development at Biozipcode, Inc..

If you wish to make a direct donation, please contact Biozipcode, Inc. directly or reach out via this inquiry form.

The Supporters of Biozipcode initiative collaborates closely with two key partners: Biozipcode, Inc. and the Shiga University of Medical Science, Department of Regenerative Medicine.

Biozipcode, Inc. was established to apply and commercialize the research findings developed at the Shiga University of Medical Science, Department of Regenerative Medicine. The company is dedicated to pioneering new approaches to diabetes treatment and side-effect-free therapies, using cell-targeting technology.

Meanwhile, the Shiga University of Medical Science, Department of Regenerative Medicine plays a crucial role as an advanced medical research institution, driving deeper exploration into this field.

Both institutions collaborate by sharing scientific expertise and resources to advance the development of innovative treatments for diabetes.

The Supporters of Biozipcode is an independent initiative operated within Studio Makyu Co., Ltd..

The initiative is primarily led and managed by Fumihisa Kojima, the CEO of Studio Makyu Co., Ltd., who oversees its operations and activities.